EIF4A2 mutations are found in 0.7% of ccRCC [54], when found in other types of cancer, these mutations are associated with unfavorable prognosis and resistance to therapy [55, 56]. Here, EIF4A2 is linked to nonpapillary renal cell carcinoma.